NCT04295993

Brief Summary

This trial aims to identify the effects of methylene blue infusion on the the micro-circulation in patients with septic shock. The investigators will evaluate various indices of micro-circulation such as: microvascular flow index, the flow heterogeneity index, the total vessel density, the perfused vessel density, and the proportion of perfused vessels.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
32

participants targeted

Target at below P25 for phase_3

Timeline
Completed

Started Mar 2020

Shorter than P25 for phase_3

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

March 3, 2020

Completed
2 days until next milestone

First Posted

Study publicly available on registry

March 5, 2020

Completed
5 days until next milestone

Study Start

First participant enrolled

March 10, 2020

Completed
6 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 10, 2020

Completed
10 days until next milestone

Study Completion

Last participant's last visit for all outcomes

September 20, 2020

Completed
Last Updated

March 5, 2020

Status Verified

March 1, 2020

Enrollment Period

6 months

First QC Date

March 3, 2020

Last Update Submit

March 3, 2020

Conditions

Outcome Measures

Primary Outcomes (1)

  • Microvascular flow index

    The image will be divided into four quadrants and the vessels \<20 μ m diameter will be assigned a score based on the predominant flow characteristics of the vessels in that quadrant (0 = absent flow; 1 = intermittent; 2 = sluggish; 3 = normal). The values in each quadrant will be averaged to give an microvascular flow index for each sublingual site at each time point. To determine heterogeneity of perfusion, the flow heterogeneity index will be calculated as the highest microvascular flow index minus the lowest microvascular flow index divided by the mean microvascular flow index.

    6 hours

Secondary Outcomes (9)

  • Total vessel density

    6 hours

  • Perfused vessel density

    6 hours

  • Proportion of perfused vessel

    6 hours

  • mean arterial pressure

    24 hours

  • serum lactate

    6 hours

  • +4 more secondary outcomes

Study Arms (2)

methylene blue group

EXPERIMENTAL

The patients in this group will receive methylene blue bolus in addition to the norepinephrine infusion.

Drug: Methylene BlueDrug: Norepinephrine infusion

Norepinephrine group

ACTIVE COMPARATOR

The patients in this group will receive norepinephrine infusion.

Drug: Norepinephrine infusion

Interventions

The patient will receive Methylene Blue bolus with a dose of 2 mg/kg over 10 minutes.

methylene blue group

The patient will receive norepinephrine infusion to maintain mean arterial pressure above 65 mmHg

Also known as: Levophed
Norepinephrine groupmethylene blue group

Eligibility Criteria

Age18 Years - 70 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Septic shock
  • The patient is on norepinephrine infusion

You may not qualify if:

  • Elevated serum creatinine (above 1.4 mg/dL)
  • Pregnancy

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Cairo University

Cairo, Egypt

Location

MeSH Terms

Conditions

Shock, Septic

Interventions

Methylene BlueNorepinephrine

Condition Hierarchy (Ancestors)

SepsisInfectionsSystemic Inflammatory Response SyndromeInflammationPathologic ProcessesPathological Conditions, Signs and SymptomsShock

Intervention Hierarchy (Ancestors)

PhenothiazinesSulfur CompoundsOrganic ChemicalsHeterocyclic Compounds, 3-RingHeterocyclic Compounds, Fused-RingHeterocyclic CompoundsEthanolaminesAmino AlcoholsAlcoholsAminesBiogenic MonoaminesBiogenic AminesCatecholaminesCatecholsPhenolsBenzene DerivativesHydrocarbons, AromaticHydrocarbons, CyclicHydrocarbons

Study Officials

  • Ahmed Mukhtar, Professor

    Professor of anesthesia

    PRINCIPAL INVESTIGATOR

Central Study Contacts

kareman abdelghaffar, Demonstrator

CONTACT

Ahmed Hasanin, Professor

CONTACT

Study Design

Study Type
interventional
Phase
phase 3
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Assistant lecturer of anesthesia and critical care medicine

Study Record Dates

First Submitted

March 3, 2020

First Posted

March 5, 2020

Study Start

March 10, 2020

Primary Completion

September 10, 2020

Study Completion

September 20, 2020

Last Updated

March 5, 2020

Record last verified: 2020-03

Data Sharing

IPD Sharing
Will not share

Locations